Top Page
Ionis Pharmaceuticals
(NASDAQ:IONS)
Ionis Pharmaceuticals (IONS) vs. SPDR S&P 500 ETF (SPY)
Ionis Pharmaceuticals Business Overview & Revenue Model
Ionis Pharmaceuticals Key Performance Indicators (KPIs)
Shows revenue generated from individual products, highlighting which drugs are driving sales and indicating the company's reliance on specific treatments for growth.
Main Street DataIonis Pharmaceuticals Earnings Call Summary
Ionis Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 966.96M | 705.14M | 787.65M | 587.37M | 810.46M | 729.26M |
| Gross Profit | 955.14M | 693.92M | 778.51M | 573.25M | 799.61M | 717.32M |
| EBITDA | -162.60M | -353.72M | -235.87M | -227.76M | -5.19M | -111.19M |
| Net Income | -256.34M | -453.90M | -366.29M | -269.72M | -28.60M | -444.26M |
Balance Sheet | ||||||
| Total Assets | 3.03B | 3.00B | 2.99B | 2.53B | 2.61B | 2.39B |
| Cash, Cash Equivalents and Short-Term Investments | 2.24B | 2.30B | 2.33B | 2.00B | 2.13B | 1.89B |
| Total Debt | 2.05B | 1.42B | 1.45B | 1.37B | 1.25B | 908.93M |
| Total Liabilities | 2.42B | 2.42B | 2.60B | 1.96B | 1.84B | 1.65B |
| Stockholders Equity | 618.00M | 588.35M | 386.69M | 572.89M | 771.74M | 743.28M |
Cash Flow | ||||||
| Free Cash Flow | -302.66M | -546.23M | -335.52M | -294.47M | 12.90M | -5.16M |
| Operating Cash Flow | -247.01M | -500.95M | -307.51M | -274.37M | 30.80M | 35.89M |
| Investing Cash Flow | 209.94M | -134.03M | -214.13M | -262.64M | 194.91M | 274.48M |
| Financing Cash Flow | 40.55M | 478.06M | 644.08M | -55.30M | 245.93M | -596.61M |
Ionis Pharmaceuticals Technical Analysis
Ionis Pharmaceuticals Risk Analysis
Ionis Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $5.89B | 30.49 | 19.66% | ― | 116.09% | 35.29% | |
74 Outperform | $5.02B | 15.04 | 22.35% | ― | 1.08% | 3.40% | |
57 Neutral | $11.80B | ― | -39.99% | ― | 20.39% | 34.00% | |
54 Neutral | $6.80B | -28.87 | -275.50% | ― | 69.83% | 22.16% | |
53 Neutral | $7.13B | -11.64 | ― | ― | 2635.74% | 4.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.58B | -5.60 | -21.37% | ― | 64.89% | -221.56% |
Ionis Pharmaceuticals Corporate Events
Ionis Pharmaceuticals Inc. faces significant risks related to its securities and the global credit markets, particularly if it fails to progress in its programs as anticipated. The company’s share price is vulnerable to fluctuations based on the timing and achievement of various clinical, regulatory, and commercial milestones, which are often based on assumptions outside its control. Failure to meet these milestones or analysts’ forecasts could lead to a decrease in the market price of its common stock, affecting investor confidence. Additionally, the volatility of its securities could complicate liquidation efforts and increase the risk of financial loss for investors.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapies for serious diseases, with a strong presence in neurology and cardiometabolic disease sectors.
Ionis Pharmaceuticals’ recent earnings call reflected a generally positive sentiment, underscored by strong revenue growth and successful product launches. The company made significant advancements in its clinical pipeline, although it continues to face challenges with operating losses and patient identification for its drug Tringolza. Overall, the positive developments seem to outweigh the challenges, painting an optimistic picture for the company’s future.
Ionis Pharmaceuticals Inc. is conducting a Phase 3 study titled ‘REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome’ to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome. This genetic disorder is caused by a deletion or mutation of the UBE3A gene, and the study aims to provide a potential treatment option for affected individuals.
Ionis Pharmaceuticals Inc. is conducting a study titled ‘ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS).’ The primary goal is to assess the safety and tolerability of ION440, a promising treatment for MECP2 Duplication Syndrome, a rare genetic disorder. This study is significant as it addresses a critical unmet medical need.
Ionis Pharmaceuticals Inc. is conducting a clinical study titled HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome. The study aims to assess the safety and tolerability of ascending doses of ION582, a drug administered via intrathecal injection, in individuals with Angelman syndrome. This research is significant as it explores potential therapeutic options for a condition with limited treatment alternatives.
Ionis Pharmaceuticals Inc. is conducting an open-label extension study titled An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG). The study aims to evaluate the safety and tolerability of olezarsen in patients with severe hypertriglyceridemia, a condition characterized by extremely high levels of triglycerides in the blood, which can lead to pancreatitis and other cardiovascular issues.
Study Overview: The Rocket Study, officially titled ‘Integrated Prospective and Retrospective Observational Study to Characterize Biomarkers and Disease Progression in Patients With Pelizaeus-Merzbacher Disease,’ aims to assess changes in specific biomarkers and neuroimaging parameters in patients with Pelizaeus-Merzbacher Disease (PMD). This study is significant as it seeks to inform the development of therapies for PMD, a rare genetic disorder affecting the central nervous system.
Study Overview: The Orbit Study, officially titled ‘A Phase 1b Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION356 in Patients With Pelizaeus Merzbacher Disease,’ aims to assess the safety and tolerability of the drug ION356. This study is significant as it targets Pelizaeus-Merzbacher Disease (PMD), a rare genetic disorder affecting the central nervous system.
Ionis Pharmaceuticals Inc. is conducting a Phase 1 study titled ‘A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy.’ The study aims to evaluate the safety and tolerability of ION464, a drug administered via intrathecal injection, in patients with multiple system atrophy (MSA). This study is significant as it explores a potential new treatment for MSA, a rare neurodegenerative disorder.
On September 22, 2025, Ionis Pharmaceuticals announced positive results from a pivotal study of zilganersen, an investigational medicine for Alexander disease (AxD), a rare neurological condition. The study showed statistically significant stabilization in gait speed and favorable safety, marking the first time a treatment has demonstrated a disease-modifying impact in AxD. Ionis plans to submit a new drug application to the FDA in early 2026, potentially transforming the treatment landscape for AxD and reinforcing Ionis’ position in addressing severe neurological diseases.
The most recent analyst rating on (IONS) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.
On September 2, 2025, Ionis Pharmaceuticals announced positive results from its Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). The studies revealed significant reductions in fasting triglycerides and acute pancreatitis events, positioning olezarsen as a potential new standard for sHTG treatment. The results demonstrated a 72% reduction in triglycerides and an 85% reduction in pancreatitis events, with favorable safety and tolerability. Ionis plans to submit a supplemental new drug application to the FDA by the end of the year, marking a significant step in their efforts to address sHTG and expand their market presence.
The most recent analyst rating on (IONS) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.
On August 21, 2025, Ionis Pharmaceuticals announced that the FDA approved DAWNZERA™ (donidalorsen) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older. DAWNZERA is the first RNA-targeted medicine for HAE, significantly reducing attack rates and offering a convenient dosing schedule. The approval was based on successful Phase 3 trial results, showing an 81% reduction in monthly HAE attack rates. This approval strengthens Ionis’ position in the market, offering a new treatment option for HAE patients, and is part of Ionis’ broader strategy to deliver life-changing medicines.
The most recent analyst rating on (IONS) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.
Ionis Pharmaceuticals Inc. recently held its earnings call, revealing a strong overall performance characterized by significant revenue growth, successful product launches, and positive pipeline developments. Despite these achievements, the company faces challenges in patient identification and pricing strategy, alongside uncertainties in data outcomes.
Ionis Pharmaceuticals Inc. is a biotechnology company specializing in RNA-targeted drug discovery and development, with a focus on creating innovative therapies for patients with severe diseases. The company operates primarily in the biopharmaceutical sector, known for its pioneering work in RNA-based medicines.